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Abstract: Bone morphogenetic proteins (BMPs) are often used with bone grafts for bone regeneration. The aim of this study was to
evaluate the effect of demineralized freeze-dried bone allografts and externally applied rhBMP-2 on bone healing in experimentally
generated defects in the calvarium of ovariectomized and nonovariectomized rats via histological and immunohistochemical assays.
The current study was carried out on 42 female Wistar rats. After ovariectomy was performed in half of the rats, the rats were divided
into three groups: control, allograft, and allograft + BMP. An experimental defect with a diameter of 4 mm was created unilaterally in
the parietal bone using a trephine dental drill and a physiodispenser with saline. All animals were euthanized at the end of week 8, and
bone tissues were analyzed histologically and immunohistochemically. The allografts produced better results in terms of calvarial defect
healing in both the ovariectomized and nonovariectomized groups compared to the control group in enhancing bone healing, whereas
BMPs combined with allografts had no positive effect on new bone formation. The allografts and BMPs applied in both groups produced
fibrous tissues rather than new bone tissue. Further comprehensive studies on the effectiveness of BMPs in the formation of new bone
tissue should be conducted in animals with estrogen deficiency.
Key words: Bone morphogenetic protein, allograft, ovariectomy, bone regeneration, rat

1. Introduction
Inadequate bone support for oral surgery and periodontal
regeneration is a major problem for surgical applications.
Additional graft materials are needed in dentistry to repair
missing bone tissue. Currently, due to their osteogenic,
osteoinductive, and osteoconductive effects, autogenous
bone grafts are considered the gold standard under certain
conditions [1]. However, other conditions, such as the
presence of a second surgical site and the failure to obtain
the desired amount of material, limit the use of autogenous
bone grafts [2]. Because of this, many researchers have
attempted to find an alternative to autografts. For instance,
allografts have been used in dentistry for a long time.
Allografts have osteoconductive and osteoinductive
effects [3]. Regrettably, the devitalization process used to
suppress the host immune response and prevent possible
disease transmission in cadaveric allografts causes the loss
of the mechanical, osteoinductive, and osteoconductive
properties of the graft [4,5]. In addition, the maturation
times of allografts are longer in defect regions than those
of autografts [6,7].

Bone morphogenetic proteins (BMPs) are well known
to induce osteogenic effects. Allografts typically contain
BMPs that accelerate mesenchymal cell migration and
attachment [3]. In both in vitro and in vivo studies of
BMP-2, which is a type of BMP, the contribution of
BMP-2 to ossification could be shown. BMP-2 promotes
periodontal and bone regeneration in some animal models
[8,9] and also induces differentiation of preosteoblast cells
and thereby increases ossification [10,11]. Fundamentally,
BMPs are types of growth factors and belong to the
transforming growth factor (TGF-β) family [12]. There
are variant BMPs that support bone regeneration, such
as BMP-2, -4, -5, -6, and -7 [13]. Recombinant human
bone morphogenetic protein-2 (rhBMP-2), generated by
recombinant DNA technology from mammalian cells, is
known to induce differentiation of osteoblasts at a cellular
level and to induce osteogenesis in animal models [14].
Bone graft materials and osteoinductive agents have a
synergistic effect [15]. The synergistic effect of BMPs and
bone grafts on bone regeneration has been demonstrated
in animal studies [11].
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In immunohistochemical studies, the type of
biomarkers used is important for analyzing, imaging, and
examining regeneration in the bone defect area [16]. For
instance, osteocalcin (OC) is a strong marker of newly
formed bone [17,18]. Osteonectin (ON) is a biological
modulator and a known proliferative agent [19]. These
biomarkers have been shown under various conditions to
control bone cell differentiation and remodeling [20,21].
Osteopontin (OPN) is also a biomarker involved in the
bone maturation and mineralization stages that occur after
the accumulation and formation of a collagen network
[22].
Osteoporosis is characterized by decreased bone
volume and deterioration of bone cells and consequently
causes bone fragility and fractures [23]. Osteoporosis
and periodontitis mainly affect bone tissues [24].
Postmenopausal osteoporosis is a condition that occurs 10
to 15 years after menopause and often leads to increases in
alveolar bone resorption and promotes periodontal tissue
degeneration [25]. Estrogens play an important role in
both inflammation and skeletal repair and remodeling by
regulating important mediators of immune function. At
the same time, estrogen inhibits osteoclast secretion [26].
There is a close relationship between bone metabolism and
estrogen deficiency in osteoporosis [27].
The objective of the current study was to evaluate the
effect of allografts and externally applied rhBMP-2 on
bone healing in experimentally generated defects in the
calvarium of ovariectomized and nonovariectomized rats
via histological and immunohistochemical assays.
2. Materials and methods
2.1. Study design
A total of 42 female Wistar rats (250-300 g) provided by
the Scientific Application and Research Center of Dicle
University (Protocol No: 12-DH-53) were used. All the
procedures described in the experimental protocols
were approved by the Animal Ethics Committee of Dicle
University (Protocol No: 2011/15, 29.03.2011). The
study was performed in accordance with the Helsinki
Declaration and with the permission of the Governmental
Animal Protection Committee. The study was performed
at the Dicle University Health Sciences and Research
Center and the Faculty of Medicine Histology and
Embryology Department. The weight changes in the
rats were determined before sacrifice. The animals were
given commercial rat chow and water ad libitum and
were maintained on a 12-h light/12-h dark cycle at a
temperature of 22 ± 1 °C.
The rats used in the study were divided into two
groups: the control (nonovariectomized rats were assigned
as the control group) and the ovariectomized group, and
each group was divided into three subgroups (n = 7).

These comprised the following: the control group: C1,
cranial empty defect; C2, defect with demineralized
freeze-dried bone allografts (DFDBAs); and C3, defect
with allograft and bone morphogenetic protein (BMP-2);
and the ovariectomized group: O1, cranial empty defect;
O2, defect with allograft; and O3, defect with allograft and
BMP-2.
2.2. Surgical procedure
The 21 rats subjected to ovariectomy were intraperitoneally
administered xylazine (3 mg/kg) and ketamine (35 mg/kg)
and then ovariectomy was performed. According to the
procedure recommended by Pires-Oliveira et al., between
the middle of the dorsum and the tail base, a 3-cmlong incision was made in the midline dorsal skin for
ovariectomy [28]. The animals were observed for infection.
At the end of day 30, all animals were anesthetized prior to
the generation of the bone defects in the calvarial zone.
After shaving the head hair, a longitudinal midsagittal
incision was made in the skin to expose the parietal
bones, and the flaps were retracted in the subperiosteal
plane to expose the parietal bones. A 4-mm diameter fullthickness critical-size cranial defect was made unilaterally
in the parietal bone using a trephine dental drill and a
physiodispenser with saline [29,30].
After the cranial defect was generated in the
nonovariectomized group, the defects were left empty in
group C1. DFDBAs (Raptos, Citagenix, Laval, QC, Canada)
were placed in the defects in group C2, and the defects
in group C3 were treated with allografts and rhBMP-2
(produced in E. coli, Gibco, Frederick, MD, USA). The
same experimental plan was used in the ovariectomized
rats.
After placement of the grafts, the flaps were sutured
with 3/0 silk sutures. No infection or side effects were
observed during the recovery period. Eight weeks after
the calvarial surgery, all of the rats were sacrificed using an
overdose of intraperitoneal ketamine hydrochloride prior
to histological and immunohistochemical evaluation.
2.3. Preparation of the biomaterial
Considering the manufacturer’s recommendations and the
dosage used in other studies, 10 μg of BMP was diluted
to 0.2 mg/mL [31,32]. An equal amount of allograft was
soaked with 12.5 µL of rh-BMP-2 solution before being
placed in the defect site.
2.4. Sample and histological process
The operation area was extracted using a saw, remaining
2 mm around each defect area. The samples were fixed
in 10% neutral buffered formaldehyde solution for 48 h,
and decalcified in 10% ethylenediaminetetraacetic acid
(EDTA) prepared in 0.1 M Tris-HCl buffer (pH 7.4) for
14 days. Subsequently, the specimens were dehydrated,
cleared, and embedded in paraffin. Then 5-µm-thick serial
sections were cut from the center of the bone defect. Four
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slides were prepared from each sample and each slide
contained a minimum of 3 sections that were at least 50µm apart. Three slides were used for immunohistochemical
detection, and the other, stained by Gomori’s method (to
determine ossification), was used for histological analysis.
2.5. Immunohistochemical staining
To perform the immunohistochemical analyses, the
streptavidin–biotin–peroxidase method [33] was
performed using the Zymed Histostain Plus Bulk Kit
(code: 85-9043, Histostain Plus Bulk Kit, Zymed, South
San Francisco, CA, USA). Sections were treated with
3% H2O2 prepared in methanol for 15 min to block
endogenous peroxidase activity after deparaffinization
and rehydration and were washed with phosphatebuffered saline (PBS). Antigen retrieval was performed in
citrate buffer (0.01 M, pH 6.0) at 95 °C for 30 min, and
the sections were allowed to cool before immunostaining.
After they were washed twice in PBS for 5 min, the
sections were treated with protein blocking solution (Ultra
V Block) at room temperature for 5–10 min to block
nonspecific staining. Then the sections were incubated
with a mouse monoclonal antibody against OPN (Santa
Cruz Biotechnology, sc-21742) and rabbit polyclonal
antibodies against OC (Santa Cruz Biotechnology, sc30044) and ON (Santa Cruz Biotechnology, sc-25574) at
a dilution of 1:200 for 20 h at 4 °C. After incubation, the
sections were washed three times in PBS for 5 min, treated
with biotinylated secondary antibody at room temperature
for 20 min, and then washed three times in PBS for 5 min.
The sections were incubated in streptavidin peroxidase
solution for 20 min and washed three times in PBS for 5
min. To visualize the reaction, the sections were treated
with 3’3-diaminobenzidine (DAB) chromogen for 5–10
min and counterstained with Mayer’s hematoxylin for 2–3
min. Negative controls were used to ensure the accuracy of

staining, and distilled water was used instead of primary
antibodies in these controls.
The intensity of the positive staining was defined as +
weak, ++ medium, +++ strong, +/++ weak to moderate,
or ++/+++ moderate to strong. The slides were examined
and photographed using a Nikon Eclipse E400 microscope
(Nikon, Tokyo, Japan) equipped with a digital camera
(Nikon Coolpix-4500) (Table 1).
2.6. Statistical evaluation
Kruskal–Wallis and Mann–Whitney U tests, which are
nonparametric test methods, were used, and statistical
analyses were considered significant for P < 0.05.
3. Results
3.1. Histological findings
At the fornix of the defect cavity in the C1 group,
formations, such as spicules, that were associated with
intramembranous ossification were observed. Fibrous
tissue was also commonly observed in the cavity space
and the presence of vascularization was noted (10×). For
the ovariectomized group (O1), no intramembranous
ossification was observed in the cavity and fibrous tissue
was formed only at the fornix of the cavity and did not show
a homogeneous distribution. In addition, vascularization
was not intense in this group (10×).
In the C2 group, the presence of regular and common
fibrous tissue in the defect area was noteworthy. It was also
determined that vascularization showed a more regular
structure (10×). The fibrous tissue around the bone graft
was poorly formed and gaps between bone grafts were
common in the ovariectomized group (O2). In addition,
while the high abundance of cellular elements in the defect
area was remarkable, vascularization was irregular (10×).
The findings obtained in the C3 group (4×) were
similar to those in the C2 group described above. Likewise,

Table 1. Staining intensity scores of OPN, OC, and ON immunoreactivity in the rat calvarium.
Extracellular matrix
OPN, OC, ON

Osteoprogenitor cells
OPN, OC, ON

Osteoblasts
OPN, OC, ON

Osteocytes
OPN, OC, ON

C1

+/++, +, +

-, -, -

+, +, -

-, -, -

C2

++, ++/+++, ++/+++

-, -, -

++, ++, ++

-, -, -

C3

++, +++, +++

-, -, -

++, ++, ++

-, -, -

O1

-, +, +

-, -, -

-, +, -

-, -, -

O2

+/++, +/++, ++

-, -, -

++, ++, ++

-, -, -

O3

+/++, ++, ++

-, -, -

++, ++, ++

-, -, -

OPN: Osteopontin, OC: Osteocalcin, ON: Osteonectin, C: Control group, C1: (Empty defect), C2: (Empty
defect + graft), C3: (Empty defect + graft + BMP), O: Ovariectomized group, O1: (Empty defect), O2:
(Empty defect + graft), O3: (Empty defect + graft + BMP), Staining intensity: +++ strong, ++ moderate,
+ weak, - negative.
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the findings in the ovariectomized group (O3) and the
O2 group were parallel. Additionally, addition of BMP to
allografts had no effect in the C3 or O3 groups (Figure 1).
3.2. Immunohistochemical evaluation
3.2.1. Osteopontin involvement
In the C1 group, osteoblast cells in the defect area showed
low involvement of OPN, and the extracellular matrix
also showed only low- to medium-level involvement of
OPN. In addition, blood vessels in the defect area were
stained (20×). OPN immunoreactivity was observed
in normal bone tissue in the O1 group, whereas OPN
immunoreactivity was observed only in blood vessels in
defect areas (4×).
In the C2 group, OPN immunoreactivity was not
observed in osteoprogenitor cells at the fornix of the
defect cavity, but moderate OPN staining was observed
in osteoblasts that formed around the bone graft. The
extracellular matrix and blood vessels showed positive
staining for OPN (4× and cropped image 40×). The
findings in the O2 group were similar to those in the C2
group, and the extracellular matrix around the bone graft
showed remarkably strong OPN staining (4×).
Osteoprogenitor cells at the fornix of the defect area
showed no OPN involvement in the C3 group. It was
determined that the osteoblast cells that formed around the
bone graft material had moderate OPN immunoreactivity
and that fibrous tissue in the defect area was abundant and
homogeneously distributed (10×). While the osteoblast
cells that formed around the bone graft showed moderate
staining, the extracellular matrix around the graft showed
minimal staining (10×) (Figure 2). The comparisons of the
parameters within the groups for OPN staining are shown
in Table 2.
3.2.2. Osteocalcin involvement
In the C1 group, OC involvement in osteoprogenitor
cells was not observed, and OC showed weak staining in
osteoblasts at the fornix of the defect cavity. It was also
determined that the extracellular matrix was dense at
the fornix of the defect cavity and that the vessels were
positively stained with OC (20×). Similar findings were
shown in the O1 group compared to the C1 group, and the
only difference was that the staining in the extracellular
matrix was not homogeneously distributed (20×).
In the C2 group, negative staining was observed in
osteoprogenitor cells at the fornix of the defect area,
but unlike the findings in the C1 group, osteoblasts that
formed in the defect area showed moderate involvement.
In addition, it was observed that the extracellular matrix
and blood vessels were intensely stained both at the fornix
of the defect area and within the defect (10×). In the O2
group, in terms of OC, the extracellular matrix showed
strong involvement at the fornix of the defect cavity, but

the involvement in the defect area was weak and localized.
While osteoprogenitor cells showed no reaction with
OC, moderate OC immunoreactivity was detected in
osteoblasts. In addition, blood vessels showed positive
staining for OC (10×).
In the C3 group, no immunoreactivity was observed
in osteoprogenitor cells except for those at the fornix
of the cavity, but moderate involvement was observed
in osteoblasts. In this group, it was observed that the
extracellular matrix was stained more intensely in the
defect area and especially around the bone graft, and
blood vessels also positively stained for OC (10×). A lack
of staining was observed in osteoprogenitor cells in the
O3 group, and moderate involvement was observed in
osteoblasts. There was staining in the extracellular matrix,
both at the fornix of the defect cavity and within the defect
area, but less staining was detected around the bone graft
compared to that detected in the C3 group. In addition,
apparent OC expression was observed in the blood vessels
(10×) (Figure 3). The comparisons of the parameters
within the groups for OC staining are shown in Table 3.
3.2.3. Osteonectin involvement
In the C1 group, ON involvement in osteoprogenitor
cells at the fornix of the defect and in osteoblasts in the
defect cavity was not found. In addition, the staining of the
extracellular matrix was weak, and blood vessels showed
moderate ON immunoreactivity (10×). The O1 group
showed results similar to those of the C1 group.
In the C2 group, a lack of ON staining was observed in
osteoprogenitor cells at the fornix of the defect area; unlike
those in the C1 group, osteoblasts that formed in the defect
area in the C2 group showed moderate ON staining. The
extracellular matrix in the fornix of the defect area was
intensely but not homogeneously stained in the cavity, and
ON expression was also detected in the blood vessels (4×
and cropped image 20×). The O2 group showed results
similar to those of the C2 group, but the extracellular
matrix was not intensely stained.
In the C3 group, osteoprogenitor cells in the fornix of
the defect area did not show ON expression, but moderate
staining of osteoblasts that formed around the bone graft
was observed. The extracellular matrix and blood vessels
showed intense ON expression (10×). In the O3 group,
while osteoprogenitor cells had no staining, which was
similar to the results in the C3 group, osteoblast cells
around the bone graft showed moderate ON staining.
The extracellular matrix in the fornix of the defect area
showed intense staining, but the staining was decreased
inside the defect area. ON expression in the blood vessels
was also observed (4×) (Figure 4). The comparisons of the
parameters within the groups for ON staining are shown
in Table 4.
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Figure 1. Histological analysis of defect areas in rat calvarial bone in the control (C1, C2, and C3) and ovariectomy (O1, O2, and O3)
groups. The defects were empty as shown in C1 and O1 and defect areas were treated with bone grafts (C2, O2) and bone grafts + bmp
(C3, O3). hb: host bone, fc: fibrous connective tissue, bg: bone graft, (*): interface between host bone and the defect, (▼): bone spicule.
Scale bars: 100 µm (C1, C2, O1, and O2); 250 µm (C3 and O3). Gomori’s staining method.
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Figure 2. OPN expression in defect areas in rat calvarial bone in the control (C1, C2, and C3) and ovariectomy (O1, O2, and O3) groups.
The formations in the groups are shown in the histochemical figure. hb: host bone, fc: fibrous connective tissue, bv: blood vessel, bg:
bone graft, (*): interface between host bone and the defect, (▼): osteoblast. Scale bars: 50 µm (C1), 100 µm (C3 and O3), 250 µm (O1,
O2, and C2; the magnification within the image is 25 µm).
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Table 2. Semiquantitative analysis of the parameters for osteopontin in calvaria. P < 0.05.
Groups

P

Parameters

n

Average rank

Different (P < 0.05) from groups

7

7.57

(2)

7

15.14

(1)

7

10.29

ns

7

5.43

(2)(3)

7

14.14

(1)

7

13.43

(1)

n

Average rank

Different (P < 0.05) from groups

(1) O1

7

5.00

(2)(3)

(2) O2

7

17.29

(1)(3)

7

10.71

(1)(2)

(1) O1

7

4.00

(2)(3)

(2) O2

7

14.00

(1)

7

15.00

(1)

(1) C1
(2) C2
(3) C3

0.0269

1

(1) C1
(2) C2
(3) C3
Groups

(3) O3

(3) O3

0.0064

3

P

Parameters

0.0004

0.0004

1

3

Parameters: 1, extracellular matrix; 2, osteoprogenitor cells; 3, osteoblasts; 4, osteocytes.
ns: nonsignificant (P > 0.05) Since average ranks of parameters 2 and 4 were equal, no significant difference
could be established (average rank = 11.00).

4. Discussion
The results suggest that the use of rhBMP-2 with allografts
may increase bone regeneration in estrogen-deficient rats.
Autografts are still acknowledged as the gold standard due
to their osteogenic, osteoconductive, and osteoinductive
properties. However, they have some disadvantages such as
limited supply and donor site morbidity [34]. Allografts,
which are produced as an alternative to autografts, are
considered the gold standard for bone regeneration and are
obtained from cadavers. Although allografts contain BMPs,
they lose some of their effectiveness in preventing disease
as a result of the sterilization procedure [4]. Bone graft
materials such as allografts are used in bone regeneration
in oral surgery and periodontology [35,36]. Many factors
affect the effectiveness of the graft material, such as the
type of graft and the growth factors, and living cells and
vascularization in the graft material and defect area
[37,38]. Additionally, the existence of osteoprogenitor cells
in the defect area directly influences bone regeneration.
Moreover, when these cells are triggered by growth factors
and have adequate vascularization, bone regeneration
occurs robustly [7,39]. rhBMP is a kind of TGF-β and was
used to enhance new bone formation in the present study.
A critical-size bone defect is defined as an intraosseous
wound that will not heal itself completely without
intervention [40,41]. In the present study, as in previous
studies, the size of the critical-size defect was selected as
4 mm [7,29]. Although it is difficult to compare human
biology and animal biology, rats are frequently used to
ensure the reproducibility of experiments and for studies
that seek to attain a ‘proof of principle’ [18,42]. The rat
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calvarial site defect model is an excellent model for bone
regeneration in the craniofacial region. As the calvarial site
is stable, defects in this site are useful for the examination of
histological and immunohistochemical parameters [18]. In
the present study, the experiment period was determined
as 8 weeks. This period was selected based on previous
studies [43–45]. Akita et al. [29] and Dazai et al. [46] stated
that endogenous bone healing was completed after 8 weeks.
Recently, the appropriate dosage of rhBMP has
become controversial. A high BMP dosage could have
negative consequences, such as osteolysis, hematoma,
and ectopic bone formation, and these could be caused by
disproportionate growth of osteoblasts [47–49]. Moreover,
Kimelman Bleich et al. claimed that even using sequestered
BMPs can cause osteolysis [50]. Additionally, the results
of a study carried out by Abdala et al. with different doses
of rhBMP (1, 3, 5, and 7 µg) showed that there were no
significant differences in new bone formation in rat
calvarial defects [51]. Pelaez et al. added different amounts
of rhBMP-2 to graft materials and examined the effect on
the amount of new bone. It was found that a dose greater
than 2.5 µg had no effect on new bone formation [43]. By
considering the presence of BMP in the allograft and based
on the results of the studies mentioned above, the dosage
of rhBMP was selected as 0.2 mg/mL in the present study.
According to the immunohistochemical results of our
study, the OC, OPN, and ON staining results in osteoblasts,
osteocytes, the extracellular matrix, and osteoprogenitor
cells were similar among the groups, and rhBMP-2 had
no effect on ossification or immunological staining in
either the nonovariectomized or ovariectomized groups.

KADİROĞLU et al. / Turk J Vet Anim Sci

Figure 3. OC expression in defect areas in rat calvarial bone in the control (C1, C2, and C3) and ovariectomy (O1, O2, and O3) groups.
The formations in the groups are shown in the histochemical figure. hb: host bone, fc: fibrous connective tissue, bv: blood vessel, bg:
bone graft, (*): interface between host bone and defect, (▼): osteoblast. Scale bars: 50 µm (C1 and O1), 100 µm (C2, C3, O2, and O3).
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Table 3. Semiquantitative analysis of the parameters for osteocalcin in rat calvaria. P < 0.05.
Groups

P

Parameters

n

Average rank

Different (P < 0.05) from groups

7

7.93

ns

7

13.21

ns

7

11.86

ns

7

4.36

(2)(3)

7

13.71

(1)

7

14.93

(1)

n

Average rank

Different (P < 0.05) from groups

(1) O1

7

11.00

ns

(2) O2

7

9.50

ns

7

12.50

ns

(1) O1

7

5.07

(2)(3)

(2) O2

7

15.00

(1)

7

12.93

(1)

(1) C1
(2) C2
(3) C3

0.0848

1

(1) C1
(2) C2
(3) C3
Groups

(3) O3

(3) O3

0.0007

3

P

Parameters

0.5134

0.0026

1

3

Parameters: 1, extracellular matrix; 2, osteoprogenitor cells; 3, osteoblasts; 4, osteocytes.
ns: nonsignificant (P > 0.05) Since average ranks of parameters 2 and 4 were equal, no significant difference
could be established (average rank = 11.00).

Ishigaki et al. revealed that OC staining of osteoblasts was
weak in the graft group [52]. Ivanovski et al. observed that
OC staining of osteoblasts and osteocytes was strong in
the graft group [53]. Another study showed that osteocyte
staining was moderate in both the ovariectomized and
nonovariectomized groups [54]. In the present study, OC
staining of osteoblasts was moderate, and no staining of
osteocytes was observed in either the ovariectomized or
nonovariectomized groups. ON staining of osteocytes was
not observed in the ovariectomized or nonovariectomized
groups in our study, and the ON staining of osteoblasts
was moderate. The results of studies by Tera et al. [52]
and Ishigaki et al. [54] were similar to those of our
study. In the literature, many immunohistochemical and
histological studies have shown that rhBMP-2 is effective
in increasing new bone formation [18,31,40,55–57]. Cheng
et al. showed that BMP-2 did not produce a statistically
significant difference in bone volume in an experimental
study in rats. They also argued that the use of allografts in
combination with BMP-2 did not achieve the full repair of
defects [58]. Koerner et al. showed that some adverse side
effects of rhBMP-2 were increased inflammatory reactions
and the expression of inflammatory cytokines [59]. When
histological and immunohistochemical studies of BMP in
the literature were examined, it was found that BMP was
used with different growth factors and agents to prevent
the side effects mentioned above. For instance, Lee et al.
reported that the use of BMP and FGF-2 together with
biphasic calcium phosphate (BCP) in an animal model
increased periodontal tissue regeneration and was more
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successful than BCP used with BMP-2 alone. The BMP-2
+ BCP results at the end of 4 weeks were better than the
BMP-2 + FGF-2 + BCP results, whereas the BMP-2 + FGF-2
+ BCP group results were better at the end of 8 weeks [11].
Similarly, Sharmin et al. reported that the combination of
vascular endothelial growth factor and BMP was superior
to BMP-2 alone [60].
Although estrogen is the primary sex hormone in
women, it plays a crucial role in bone regeneration and
homeostasis in both women and men [26]. Estrogen
deficiency leads to both early and late osteoporosis in
postmenopausal women and increases the occurrence of
osteoporosis in older men [61]. Ovariectomy is considered
the most common method to induce osteopenia [54].
Similar to the results of the study by Tera et al. [54],
the immunohistochemical markers did not show any
alterations due to osteopenia. Several animal studies
have shown delayed bone repair effects similar to those
observed in the present study [62–64]. Fuegl et al. stated
that the enhancement of bone formation was minimal in
ovariectomized rats [65]. In another study, it was shown
that the amount of newly formed bone was small and that
bone formation was slow [66]. Durão et al. correspondingly
indicated that the rate of new bone formation was slow
[67]. Song et al. reported that bone resorption in the
ovariectomized rat cortical tibial area started at the end of
the eighth week, and bone formation was not observed at
the end of the fourth week [68]. In a study conducted by
Yang et al., bone formation occurred at the twelfth week in
ovariectomized rats [69].
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Figure 4. ON expression in defect areas in rat calvarial bone in the control (C1, C2, and C3) and ovariectomy (O1, O2, and O3) groups.
The formations in the groups are shown in the histochemical figure. hb: host bone, fc: fibrous connective tissue, bv: blood vessel, bg:
bone graft, (*): interface between host bone and defect, (▼): osteoblast. Scale bars: 100 µm (C1, C3, O1, and O2), 250 µm (O3 and C2;
the magnification within the image is 25 µm).
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Table 4. Semiquantitative analysis of the parameters for osteonectin in rat calvaria. P < 0.05.
Groups
(1) C1
(2) C2
(3) C3
(1) C1
(2) C2
(3) C3
Groups
(1) O1
(2) O2
(3) O3
(1) O1
(2) O2
(3) O3

P

Parameters

0.0004

1

0.0002

3

P

Parameters

0.0013

1

0.0004

3

n

Average rank

Different (P < 0.05) from groups

7
7
7
7
7
7

4.00
13.50
15.50
4.00
14.50
14.50

(2)(3)
(1)
(1)
(2)(3)
(1)
(1)

n

Average rank

Different (P < 0.05) from groups

7
7
7
7
7
7

4.71
13.71
14.57
4.00
14.50
14.50

(2)(3)
(1)
(1)
(2)(3)
(1)
(1)

Parameters: 1, extracellular matrix; 2, osteoprogenitor cells; 3, osteoblasts; 4, osteocytes.
Since average ranks of parameters 2 and 4 were equal, no significant difference could be established (average
rank = 11.00).

It is known that regeneration in the calvarial region
can be more difficult to induce than regeneration in
the tibial region. In a previous study, it was shown that
experimentally created defects in the calvarial region
may lead to insufficient supply of blood vessels and a lack
of osteoprogenitor cells. Thus, it has been claimed that
calvarial defects result in a poor osteogenic response and
a challenging recovery environment during the evaluation
of therapeutic agents [65]. In the present study, considering
the weak effect of BMPs and above all the lack of estrogen,
the poor conditions in the calvarial region and the loss of
periosteum were considered to have a negative effect on
bone healing.
In conclusion, in both the control and ovariectomized
groups, although there was an improvement in terms of
the production of fibrous tissue in the allograft groups, no
ossification areas were observed in the defects treated with
allografts/allografts + BMPs. In addition, the control group

showed a more positive result for fibrous tissue compared
to the ovariectomy group. In addition, OPN, OC, and
ON were expressed in the matrix and osteoblasts in areas
where ossification was expected, but bone formation was
not sufficient. Further studies are necessary to investigate
the use of bone regeneration biomaterials in estrogen
deficiency conditions.
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